T

TG Therapeutics
D

TGTX

34.610
USD
0.09
(0.26%)
Market Open
Volume
41,104
EPS
0
Div Yield
-
P/E
-348
Market Cap
5,386,020,556
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRVS
    -0.31000
    (-3.64%)
    8.21000 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    J
    JNCE
    0.08500
    (5.31%)
    1.68000 USD
    K
    KPTI
    -0.02960
    (-3.54%)
    0.80740 USD
    M
    MYOV
    0
    (0%)
    0.000000 USD
    P
    PBYI
    -0.57500
    (-19.23%)
    2.41500 USD
    More
News

Title: TG Therapeutics

Sector: Healthcare
Industry: Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.